EmeraMed: who we are…
EmeraMed Limited is a privately held limited liability company (corporation) organized and headquartered in the Republic of Ireland. The Company currently operates in Ireland, Sweden and the United States. The Company’s owner group is primarily composed of physicians, dentists, and patients with personal experience of the product from when it was previously sold as a dietary supplement. If you are interested in learning more about the Company, please use our Contact page to request additional information.
This information is provided for information purposes only and does not constitute an offer to sell or a solicitation of an offer to buy any security in any jurisdiction.
Emeramide: A unique chelator
Emeramide is a lipophilic, di-thiol metal chelator, and antioxidant. Orphan Drug Designation was received for the treatment of mercury toxicity in the EU and US in 2012. Pre-clinical safety studies, a Phase I trial, and two Phase IIa trials have been performed. The Company is working to obtain marketing authorization in the EU and the US for the treatment of mercury toxicity in both humans and animals. A Phase IIb pivotal study began in October, 2018 in Colombia South America.
International Non-Proprietary Name (INN): Emeramide
Molecule: N,N’-bis(2-mercaptoethyl)isophthalamide (NBMI)
Our research and development efforts are committed to improving the health and well being of people and animals around the world by applying sound principles of medicine and science and working collaboratively with internationally renowned researchers and university centers.
Meet Our Team
The scientific literature has firmly established that mercury causes a biochemical train wreck especially in the brain where it is linked to a host of neurological illnesses and oxidative stress.
Discover The Future of Health
We are committed to improving health by way of our unique metal chelator and antioxidant, Emeramide